Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.93 USD | -2.62% | -13.64% | +18.62% |
May. 09 | Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.62% | 190M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- ADVM Stock
- News Adverum Biotechnologies, Inc.
- Adverum Biotechnologies : Chardan Downgrades Adverum Biotechnologies to Neutral Rating From Buy on Eye Drug Side Effects, Adjusts Price Target to $5 From $20